Health4 years ago
Gilead will charge $2,340 per patient for COVID-19 drug candidate remdesivir
Gilead Sciences Inc. will charge $2,340 for a five-day treatment of its COVID-19 drug candidate remdesivir in the United States and other developed countries. The U.S....